Connect the biology
Map how targets, pathways, cells, organs, drugs, and indications relate. These interconnected relationships provide an independent biological foundation for evaluating a program.
HOW IT WORKS
From biological connections to comparable development risk.
MBRS computes mechanistic and biological relationships, measures programs on a common basis, and places each asset within its competitive indication ecosystem.
Turn asymmetric evidence into comparable measurements
Biological evidence is uneven: signals vary in scale, density, and direction. MBRS brings these differences into a standardized measurement frame, so programs can be compared on equivalent terms without erasing their underlying distinctions. Positions are displayed in the MBRS visual ring and distilled into calibrated biological risk scores.
Conceptual illustration only; not actual program scores or an exact display of the computational transformation.
Add program-specific evidence
Submitted scientific documents and development intelligence are mapped to the relevant asset and biological ecosystem, while private submissions remain account-scoped.
Reassess the ecosystem
As new evidence or competitors emerge, MBRS can recalculate an asset’s biological position and assemble comparative reports from the updated analysis.
Keep the record
Versioned reports preserve the model, scoring snapshot, sources, and issuance date so clients can compare earlier and newer assessments.
READING THE RESULTS
Complementary measures, not a single verdict.
MBRS
Biological development favorability, differentiation and competitive positioning.
Bio-Score
Beneficial and adverse effects in the specified indication.
Worth
Biology-informed estimates of development-stage worth, rather than market price.
Clinical development
An independent Phase I–III progression reference, separate from MBRS and Bio-Score.
Context
A biological baseline can be reassessed in a competitive ecosystem.
Interpretation
Favorable, mixed and unfavorable boundaries depend on the indication and model version.
All scores support biological diligence and comparative investigation. They are not experimental proof, clinical guarantees, or investment advice.